SEARCH

SEARCH BY CITATION

References

  • 1
    Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61: 3749.
  • 2
    Chapple CR, Artibani W, Cardozo LD et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 2005; 95: 33540.
  • 3
    Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997; 50 (6A Suppl.): 1007; discussion 108–10.
  • 4
    Liberman JN, Hunt TL, Stewart WF et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001; 57: 104450.
  • 5
    Wein AJ. Diagnosis and treatment of the overactive bladder. Urology 2003; 62 (5 Suppl. 2): 207.
  • 6
    Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004; 3: 4653.
  • 7
    Kobayashi S, Ikeda K, Miyata K. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. Life Sci 2004; 74: 84353.
  • 8
    Ikeda K, Kobayashi S, Suzuki M et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 97103.
  • 9
    Cardozo L. Randomized, double-blind placebo-controlled trial of once-daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172: 19191924.
  • 10
    Chapple CR, Rechberger T, Al-Shukri S et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93: 30310.
  • 11
    Gittelman MC, Kaufman J. Solifenacin succinate 10 mg once daily significantly improves symptoms of overactive bladder. Presented at the 17th International Federation of Gynecology and Obstetrics World Congress, Abstract 111. November 2–7, 2003; Santiago, Chile.
  • 12
    Gittelman M. The efficacy and safety of solifenacin in adults with overactive bladder: a multicenter, placebo-controlled study. Int J Gynaecol Obstetr 2003; 83 (Suppl. 3): 94 (abstract TP76).
  • 13
    Mattiasson A, Djurhuus JC, Fonda D et al. Standardization of outcome studies in patients with lower urinary tract dysfunction: a report on general principles from the Standardisation Committee of the International Continence Society. Neurourol Urodyn 1998; 17: 24953.
  • 14
    Kelleher CJ, Cardozo L, Chapple CR et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005; 95: 815.
  • 15
    Kelleher CJ, Pleil AM, Reese PR et al. How much is enough and who says so? BJOG, 2004; 111: 60512.
  • 16
    Payne C, Kelleher CJ. Redefining response in overactive bladder syndrome – impact on quality of life. Presented at the 36th International Continence Society Congress, August 31–September 2 2005, Abstract 310. November 2–7, 2003; Montreal, Canada.
  • 17
    Haab F, Cardozo L, Chapple C et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005; 47: 37684.
  • 18
    Haab FL, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004; 45: 4209; discussion 429.
  • 19
    Van Kerrebroeck P, Kreder K, Jonas U et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57: 41421.
  • 20
    Diokno AC, Appell RA, Sand PK et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78: 68795.
  • 21
    Zinner N, Gittelman M, Harris R et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171 (6 Pt 1): 23115.
  • 22
    Chapple C, Ballanger P, Hatzichristou D et al. Improvements in bladder condition in OAB perceived and experienced by patients in a solifenacin vs. tolterodine multinational trial (STAR study). Neurol Urodyn 2005; 24: 401598 (abstract 111).
  • 23
    Chapple CR, Martinez-Garcia R, Selvaggi L et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 46470.
  • 24
    Reese PR, Pleil AM, Okano GJ et al. The Star study: analysis of symptom severity and treatment response in overactive bladder. Proc Eur Assoc Urol 2005 (abstract 380).
  • 25
    Reese PR, Pleil AM, Okano GJ et al. Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder. Qual Life Res 2003; 12: 427442.